Targeted therapy of cancer: new roles for pathologists—prostate cancer

[1]  P. Karakiewicz,et al.  Prostate cancer-specific survival in men treated with hormonal therapy after failure of radical prostatectomy. , 2007, European urology.

[2]  Y Pawitan,et al.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.

[3]  R. Eeles,et al.  Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.

[4]  Jianfeng Xu,et al.  Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array , 2006, Genes, chromosomes & cancer.

[5]  Zhiyong Guo,et al.  Regulation of androgen receptor activity by tyrosine phosphorylation. , 2006, Cancer cell.

[6]  T. Golub,et al.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.

[7]  R. Henrique,et al.  TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. , 2006, Neoplasia.

[8]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[9]  Michael Ittmann,et al.  Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.

[10]  P. Febbo,et al.  Defining aggressive prostate cancer using a 12-gene model. , 2006, Neoplasia.

[11]  I. Panagopoulos,et al.  Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. , 2006, Genes, chromosomes & cancer.

[12]  P. Karakiewicz,et al.  25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. , 2006, The Journal of urology.

[13]  A. Evans,et al.  Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. , 2006, Neoplasia.

[14]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[15]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[16]  M. Rubin,et al.  Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. , 2005, Urology.

[17]  John T. Wei,et al.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. , 2005, Cancer cell.

[18]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.

[19]  M. Gleave,et al.  A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. , 2005, Journal of the National Cancer Institute.

[20]  G. Glinsky,et al.  Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. , 2005, The Journal of clinical investigation.

[21]  Debashis Ghosh,et al.  Decreased α-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death , 2005, Cancer Epidemiology Biomarkers & Prevention.

[22]  T. Golub,et al.  Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. , 2005, The Journal of urology.

[23]  M. Kattan,et al.  Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy , 2005, BJU international.

[24]  Ronglai Shen,et al.  Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. , 2004, Neoplasia.

[25]  Peter F Thall,et al.  Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Ni,et al.  Functional Domain and Motif Analyses of Androgen Receptor Coregulator ARA70 and Its Differential Expression in Prostate Cancer* , 2004, Journal of Biological Chemistry.

[27]  Thomas Wheeler,et al.  High Level of Androgen Receptor Is Associated With Aggressive Clinicopathologic Features and Decreased Biochemical Recurrence-free Survival in Prostate: Cancer Patients Treated With Radical Prostatectomy , 2004, The American journal of surgical pathology.

[28]  Jian Hui Wu,et al.  The androgen receptor gene mutations database (ARDB): 2004 update , 2004, Human mutation.

[29]  Tomoaki Tanaka,et al.  Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor. , 2004, Oncology reports.

[30]  C. Heinlein,et al.  Androgen receptor in prostate cancer. , 2004, Endocrine reviews.

[31]  W. Gerald,et al.  Gene expression profiling predicts clinical outcome of prostate cancer. , 2004, The Journal of clinical investigation.

[32]  Zhiyong Guo,et al.  Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells , 2004, Oncogene.

[33]  M. Tenniswood,et al.  Emergence of metastatic hormone‐refractory disease in prostate cancer after anti‐androgen therapy , 2004, Journal of cellular biochemistry.

[34]  S. Varambally,et al.  The Role of Metastasis-Associated Protein 1 in Prostate Cancer Progression , 2004, Cancer Research.

[35]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  P. Koivisto,et al.  Androgen Receptor Mutations in High-Grade Prostate Cancer before Hormonal Therapy , 2003, Laboratory Investigation.

[37]  Desok Kim,et al.  Androgen receptor gene amplification and protein expression in recurrent prostate cancer. , 2003, The Journal of urology.

[38]  G. Chatta.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer , 2003 .

[39]  K. Grigor,et al.  Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer , 2003, British Journal of Cancer.

[40]  Michael M Lieber,et al.  Journal Review , 2003, International Society of Hair Restoration Surgery.

[41]  P. Kantoff,et al.  Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. D. De Marzo,et al.  Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? , 2003, The Journal of clinical endocrinology and metabolism.

[43]  N. Ikeda,et al.  55 kDa nuclear matrix protein (nmt55) mRNA is expressed in human prostate cancer tissue and is associated with the androgen receptor , 2003, International journal of cancer.

[44]  Arul M Chinnaiyan,et al.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. , 2003, Journal of the National Cancer Institute.

[45]  D. Neal,et al.  Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development , 2003, Oncogene.

[46]  P. Walsh.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2003, The Journal of urology.

[47]  M. Tsai,et al.  Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer , 2003, Oncogene.

[48]  M. Vihinen,et al.  Pattern of Somatic Androgen Receptor Gene Mutations in Patients with Hormone-Refractory Prostate Cancer , 2002, Laboratory Investigation.

[49]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[50]  A. Z. D. Ziel-van der Made,et al.  Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer , 2002, International journal of cancer.

[51]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[52]  P. Koivisto,et al.  Androgen Receptor Alterations in Prostate Cancer Relapsed during a Combined Androgen Blockade by Orchiectomy and Bicalutamide , 2001, Laboratory Investigation.

[53]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[54]  J. Isaacs,et al.  Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. , 2001, Cancer research.

[55]  F. S. French,et al.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.

[56]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .

[57]  B. Foster,et al.  Hormone Status Selects for Spontaneous Somatic Androgen Receptor Variants That Demonstrate Specific Ligand and Cofactor Dependent Activities in Autochthonous Prostate Cancer* , 2001, The Journal of Biological Chemistry.

[58]  Jinhua Lu,et al.  Ligand- and Coactivator-mediated Transactivation Function (AF2) of the Androgen Receptor Ligand-binding Domain Is Inhibited by the Cognate Hinge Region* , 2001, The Journal of Biological Chemistry.

[59]  O. Cussenot,et al.  Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. , 2001, Cancer research.

[60]  T. Tammela,et al.  Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. , 2000, The Journal of urology.

[61]  J. Eastham,et al.  Androgen receptor mutations in prostate cancer. , 2000, Cancer research.

[62]  J. Schleutker,et al.  Androgen receptor gene mutations in hormone‐refractory prostate cancer , 1999, The Journal of pathology.

[63]  M. Gleave,et al.  Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[64]  P. Koivisto,et al.  Androgen receptor gene amplification increases tissue PSA protein expression in hormone‐refractory prostate carcinoma , 1999, The Journal of pathology.

[65]  E. Small,et al.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.

[66]  S. Yeh,et al.  From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[67]  J. Isaacs,et al.  The biology of hormone refractory prostate cancer. Why does it develop? , 1999, The Urologic clinics of North America.

[68]  Ximing J. Yang,et al.  Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? , 1999 .

[69]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[70]  P. Stattin,et al.  Early castration‐induced upregulation of transforming growth factor β1 and its receptors is associated with tumor cell apoptosis and a major decline in serum prostate‐specific antigen in prostate cancer patients , 1999, The Prostate.

[71]  H. Klocker,et al.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.

[72]  T. H. van der Kwast,et al.  Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. , 1998, Human pathology.

[73]  P. Koivisto.  Aneuploidy and rapid cell proliferation in recurrent prostate cancers with androgen receptor gene amplification , 1997, Prostate Cancer and Prostatic Diseases.

[74]  G. Bubley,et al.  Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  V. Reuter.  Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. , 1997, Urology.

[76]  L. Nazareth,et al.  Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway* , 1996, The Journal of Biological Chemistry.

[77]  G. Buchanan,et al.  Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[78]  T. Tammela,et al.  Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. , 1995, The American journal of pathology.

[79]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[80]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[81]  L. Baert,et al.  Morphologic and lmmunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies , 1994, Cancer.

[82]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[83]  J. Moul,et al.  Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. , 1994, Cancer research.

[84]  D. Chopin,et al.  Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. , 1993, The American journal of pathology.

[85]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[86]  N. Kyprianou,et al.  Effect of Transforming Growth Factor-β1 on Proliferation and Death of Rat Prostatic Cells* , 1990 .

[87]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[88]  Zhiyong Guo,et al.  Regulation of Androgen Receptor Activity by Tyrosine Phosphorylation (DOI:10.1016/j.ccr.2006.08.021) , 2007 .

[89]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[90]  D. Horsfall,et al.  Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. , 2001, Molecular endocrinology.

[91]  P. Schellhammer,et al.  Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. , 1999, Urology.

[92]  T. Mukhopadhyay,et al.  Antisense therapy for cancer. , 1995, The cancer journal from Scientific American.

[93]  C. Tempany,et al.  The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia , 1993, The Prostate.

[94]  M. Stephenson,et al.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.